AI Startup Deep Longevity Launches With Series A Financing and New AI System to Tackle Aging-related Diseases
Summary
We are happy to announce this round of funding provided by the top experts in longevity, biotechnology, and artificial intelligence. Analyzing millions of anonymized samples from multiple data types — from blood biochemistry, cell count, protein-coding genes to gut bacteria — the team identified aging-related biomarkers for diseases like diabetes, sarcopenia and NASH, and has developed the industry’s broadest portfolio of deep learning-based aging clocks. ETP Ventures and HLPIVF are investing in Deep Longevity because of their proven technology leadership in the development of AI-based aging clocks using many data types. www.DeepLongevity.com Human Longevity, Inc. is a genomics-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLPIVF is establishing a synergistic ecosystem of longevity and performance focused companies to dramatically increase the volume and effectiveness of life-affirming diagnostics and therapeutics.